AstraZeneca’s EUR 135 Million Investment in France
On January 21st, 2019, AstraZeneca inaugurated the extension of the group’s industrial site in the city of Dunkirk in Northern France. The launch was attended by Secretary of State to…
Address: 143/147 Bd Anatole France, Saint Denis 93285,France
Tel: +33 (0)1 55 87 30 00
The French Agency for the Safety of Health Products (AFSSAPS) was created by the Act of 1 July 1998 establishing a watchdog and security and safety. This is a public institution under the State supervision of the Ministry of Health. Afssaps’s mission is to ensure job security, quality and proper use of these health products.
Its jurisdiction applies to medicines and raw materials, medical devices and medical devices in vitro diagnostic (or laboratory reagents), for therapeutic products and biological products of human origin (labile blood products, organs, tissues, cells, products of gene and cell therapies), cosmetics and tattoo products.
AFSSAPS is an integeral piece of the public health system. Its activity assessment, monitoring and inspection is based on a high-level expertise to make available health products as safe as possible. It extends into the development and dissemination of information tailored to the needs of health professionals and the public. Moreover, AFSSAPS ensures that each patient receives treated products including pharmaceutical quality, the safety profile and efficacy are demonstrated and validated.
* Public Institution of the State created March 9, 1999, under supervision of the Minister for Health
* A team of nearly a thousand professionals
* More than 2,000 experts meeting in committees and working groups
* Laboratories in Saint-Denis, Lyon and Montpellier
* An operating budget of 109.6 million € for 2009
Pharmacopée
Actualité
Qu’est-ce que la Pharmacopée ?
La Pharmacopée française – 11e édition
Monographies en enquête publique
Réglementation
On January 21st, 2019, AstraZeneca inaugurated the extension of the group’s industrial site in the city of Dunkirk in Northern France. The launch was attended by Secretary of State to…
Franck Puget, managing director for CSL Behring in France, discusses the blood plasma specialist’s commitment to France, building bridges with public authorities, and regulatory attitudes towards rare disease treatments. …
Guillaume El Glaoui, co-founder and CEO of Laboratoires Majorelle, discusses what spurred the creation of the company, its success of gaining the first reimbursement ever of a condom in France,…
Eric Goupil, CEO of Unither Pharmaceuticals, discusses the company’s development strategy moving forward after the completion of a leveraged buyout in 2017. Additionally, Goupil shares the CDMO’s innovation capabilities as…
Mathilde Lignot-Leloup, director of the French Social Security, provides a fascinating look into the French social system and speaks about its ongoing transformation. She elaborates on change management processes within…
Thierry Hulot, president biopharma of Merck France, explains how France has become more open to diversity, while still needing significant reforms in the healthcare sector to remain competitive. He also…
Pascal Joly, general manager of Medac France, explains how he and his executive team have built the French affiliate from scratch, while highlighting the importance of gaining swift market access…
Guy Maugis, president of the Franco-German Chamber of Commerce and Industry, explains the impact of the Macron government on the attractiveness of France as well as the importance of a…
Philippe Truelle, President of CDM Lavoisier, highlights the financial impact of the EU’s Falsified Medicines Directive (FMD) on SMEs across Europe and explains how France is becoming increasingly attractive to…
Frédéric Collet, president Novartis France and general manager oncology explains the rationale behind Novartis’s consistent investment in France, the current shift in the company’s corporate culture and the main challenges inherent to…
In this exclusive interview, David Loew, executive vice president of Sanofi Pasteur, discusses the future of vaccines in France and the rest of the world, their strategic role in reducing…
Nicolas Bardonnet of Promega France discusses the standout growth of the company on the occasion of its 40th anniversary, collaboration with France’s biotech clusters and the growth drivers of the…
See our Cookie Privacy Policy Here
